Pfizer Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 17.89
Dividend & Yield1.64$ (4.08%)
Beta 0.58
Market capitalization 231.22B
Operating cash flow 29.27B
ESG Scores 25.3

Company description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial Ratios
Quick Ratio1.19
Working Capital1.29
Return On Equity0.28
Debt To Equity0.47
Fixed Asset Ratio0.18
Fixed Interest Cover20.79

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Change To Liabilities -341M 355M 1.24B 1.19B
Total Cashflows From Investing Activities -3.94B -4.27B -22.55B -15.78B
Net Borrowings 8.76B -12.76B -1.1B -3.52B
Total Cash From Financing Activities -8.48B -9.65B -9.82B -14.83B
Change To Operating Activities -1.37B 1.39B 16.5B -6.5B
Issuance Of Stock
Net Income 16.03B 9.16B 21.98B 31.37B
Change In Cash 125M 475M 159M -1.51B
Effect Of Exchange Rate -32M -8M -59M -165M
Total Cash From Operating Activities 12.59B 14.4B 32.58B 29.27B
Depreciation 5.71B 4.66B 5.1B 5.03B
Change To Account Receivables -1.12B -1.27B -3.81B 261M
Other Cashflows From Financing Activities -341M 11.55B 16M -335M
Change To Netincome -5.25B 887M -7.31B -2.68B
Capital Expenditures -2.05B -2.23B -2.71B -3.24B

Income Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Research Development 7.72B 8.71B 10.36B 11.43B
Income Before Tax 11.32B 7.04B 24.31B 34.73B
Net Income 16.03B 9.16B 21.98B 31.37B
Selling General Administrative 12.77B 11.42B 9.56B 12.2B
Gross Profit 33.06B 33.27B 50.6B 66.23B
Ebit 8.14B 9.79B 26.98B 39B
Operating Income 8.14B 9.79B 26.98B 39B
Interest Expense -1.57B -1.45B -1.29B -1.24B
Income Tax Expense 583M 370M 1.85B 3.33B
Total Revenue 40.91B 41.65B 81.29B 100.33B
Cost Of Revenue 7.85B 8.38B 30.69B 34.1B
Total Other Income ExpenseNet 3.18B -2.75B -2.67B -4.27B
Net Income From Continuing Ops 10.74B 6.67B 22.46B 31.4B
Net Income Applicable To Common Shares 16.02B 9.16B 21.98B 31.37B

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Total Liabilities 104.15B 90.76B 104.01B 101.29B
Total Stockholder Equity 63.13B 63.24B 77.2B 95.66B
Other Current Liabilities 11.67B 12.12B 26.73B 23.44B
Total Assets 167.59B 154.23B 181.48B 197.21B
Common Stock 468M 470M 473M 476M
Other Current Assets 6.53B 3.63B 3.82B 5.02B
Retained Earnings 97.67B 90.39B 103.39B 125.66B
Treasury Stock -122.44B -116.3B -117.26B -122.27B
Cash 1.12B 1.79B 1.94B 416M
Total Current Liabilities 37.3B 25.92B 42.67B 42.14B
Other Stockholder Equity -11.64B -5.31B -5.9B -8.3B
Property, Plant, and Equipment 14.26B 15.13B 17.72B 19.28B
Total Current Assets 32.8B 35.07B 59.69B 51.26B
Net Tangible Assets -19.01B -14.65B 2.85B 916M
Net Receivables 9.51B 11.18B 15.74B 14.53B
Accounts Payable 3.89B 4.28B 5.58B 6.81B


Insider Transactions

Here are the insider transactions of stock shares related to Pfizer Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SUSMAN SALLYConversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer72.98k
JOHNSON RADY AConversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer33.65k
HWANG ANGELAConversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer20.27k
DAMICO JENNIFER B.Conversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer11.15k
SAHNI PAYALConversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer8.92k
MCDERMOTT MICHAELConversion of Exercise of derivative security at price 22.89 per share.D2023-02-24Officer14.18k
DAMICO JENNIFER B.Stock Award(Grant) at price 0.00 per share.D2023-02-23Officer3.1k
SUSMAN SALLYConversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer76.04k
JOHNSON RADY AConversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer31.56k
HWANG ANGELAConversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer57.03k
DAMICO JENNIFER B.Conversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer10.46k
SAHNI PAYALConversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer15.21k
MCDERMOTT MICHAELConversion of Exercise of derivative security at price 30.17 per share.D2023-02-22Officer13.31k
BOURLA ALBERTConversion of Exercise of derivative security at price 22.89 - 30.17 per share.D2022-12-16Chief Executive Officer222.33k
LANKLER DOUGLAS MConversion of Exercise of derivative security at price 22.89 - 30.17 per share.D2022-12-14Officer101.66k
DOLSTEN MIKAEL GConversion of Exercise of derivative security at price 30.17 - 38.71 per share.D2022-11-07Officer79.11k
DAMICO JENNIFER B.Sale at price 53.96 per share.D2022-06-07Officer4.22k
DENTON DAVID MStock Award(Grant) at price 0.00 per share.D2022-05-31Chief Financial Officer61.27k
DAMICO JENNIFER B.Sale at price 50.50 per share.D2022-05-16Officer4k
SAHNI PAYALSale at price 49.84 per share.D2022-05-13Officer1.41k
CARAPEZZI WILLIAM R JRSale at price 50.00 per share.D2022-05-12Officer32.91k
LANKLER DOUGLAS MSale at price 49.41 per share.D2022-05-12Officer38.27k
SUSMAN SALLYStock Gift at price 0.00 per share.D2022-05-11Officer5k
DOLSTEN MIKAEL GSale at price 49.31 - 49.36 per share.D2022-05-11Officer63.9k
PAO WILLIAM PH.D.Stock Award(Grant) at price 0.00 per share.D2022-03-31Officer115.9k
DOLSTEN MIKAEL GConversion of Exercise of derivative security at price 27.34 - 38.71 per share.D2022-03-03Officer102.46k
CARAPEZZI WILLIAM R JRConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer21.19k
D AMELIO FRANK AConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer127.16k
SUSMAN SALLYConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer63.58k
LANKLER DOUGLAS MConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer77.71k
JOHNSON RADY AConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer29.32k
HWANG ANGELAConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25President12.72k
DAMICO JENNIFER B.Conversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer9.71k
MCDERMOTT MICHAELConversion of Exercise of derivative security at price 25.60 per share.D2022-02-25Officer12.34k
DAMICO JENNIFER B.Stock Award(Grant) at price 0.00 per share.D2022-02-24Officer2.89k
CARAPEZZI WILLIAM R JRConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer25.63k
D AMELIO FRANK AConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer153.79k
SUSMAN SALLYConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer76.89k
LANKLER DOUGLAS MConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer115.34k
JOHNSON RADY AConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer35.46k
HWANG ANGELAConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer21.36k
DAMICO JENNIFER B.Conversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer11.75k
SAHNI PAYALConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer13.88k
MCDERMOTT MICHAELConversion of Exercise of derivative security at price 27.34 per share.D2022-02-23Officer14.95k
DOLSTEN MIKAEL GConversion of Exercise of derivative security at price 30.17 per share.D2021-12-17Officer71.19k
BOURLA ALBERTConversion of Exercise of derivative security at price 25.60 - 27.34 per share.D2021-12-17Chief Executive Officer123.06k
JOHNSON RADY ASale at price 53.37 - 53.51 per share.D2021-12-03Officer19k
MACKENZIE ALEXANDER RSale at price 54.26 per share.D2021-12-02Officer41.36k
SUSMAN SALLYSale at price 54.43 - 54.65 per share.D2021-11-26Officer44.31k
LANKLER DOUGLAS MSale at price 54.17 - 54.55 per share.D2021-11-26Officer40k
HWANG ANGELASale at price 49.59 - 49.62 per share.D2021-11-12Officer26.17k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Pfizer Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Pfizer Inc

Here is the result of two systematic investment strategies applied to Pfizer Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Pfizer Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Pfizer Inc:

Pfizer Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 18.67% on the backtest period.

Performance at glance

Performance

18.67 %

Latent gain

414.7 $

Invested capital

2221.7 $

Annualized return

4.51 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Pfizer Inc

This is the result of two momentum investment strategies applied to Pfizer Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Pfizer Inc

The following chart shows all the entries opened by the momentum investment system on Pfizer Inc:

Pfizer Inc momentum entries
  • The first momentum investment strategy would give 21.06% of return on Pfizer Inc. That represents 1024.35$ of latent gain with 4863.61$ of employed capital.
  • The second momentum investment strategy would give 23.07% of return on Pfizer Inc. That represents 790.64$ of latent gain with 3427.6$ of employed capital.
Performance at glance (1Q Momentum)

Performance

21.06 %

Latent gain

1024.35 $

Invested capital

4863.61 $

Annualized return

12.52 %
Performance at glance (2Q Momentum)

Performance

23.07 %

Latent gain

790.64 $

Invested capital

3427.6 $

Annualized return

6.3 %

Momentum equity curve on Pfizer Inc

The following chart shows the equity curve of the two momentum strategies applied to Pfizer Inc:

Pfizer Inc momentum equity

Note: the dividends potentially given by Pfizer Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pfizer Inc

The following chart shows the employed capital evolution of the two momentum strategies on Pfizer Inc since the beginning:

Pfizer Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Pfizer Inc

Buy the dip entry openings on Pfizer Inc

Pfizer Inc

The performance achieved by the robo-advisor on Pfizer Inc is 26.8%. That represents 594.31$ of latent gain with 2217.85$ of employed capital. The following chart shows Pfizer Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Pfizer Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

26.8 %

Latent gain

594.31 $

Invested capital

2217.85 $

Annualized return

12.52 %

Equity curve of the strategy applied to Pfizer Inc

The following chart shows the result of the investment strategy applied to Pfizer Inc:

Pfizer Inc

Note: the dividends potentially given by Pfizer Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pfizer Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Pfizer Inc:

Pfizer Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Pfizer Inc

In this section, I will compare the three previous investment strategies applied to Pfizer Inc.

Equity curve comparison on Pfizer Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Pfizer Inc investment strategy comparison

Employed capital comparison on Pfizer Inc

Pfizer Inc investment comparison

Performance comparison on Pfizer Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 18.67% 414.7$ 2221.7$ 4.51%
Momentum 1 quarter 21.06% 1024.35$ 4863.61$ 5.4%
Momentum 2 quarters 23.07% 790.64$ 3427.6$ 6.3%
Non-directional 26.8% 594.31$ 2217.85$ 12.52%
Annualized return comparison

Automatic investment

4.51 %

Momentum 1Q

6.3 %

Momentum 2Q

6.3 %

Non-directional

12.52 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Pfizer Inc:

Positive correlations

Most correlated stocks this year

  • Pfizer Inc

  • Most correlated stocks last 3 months

  • SUPERACTIVE GP
  • Pfizer Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SPDR Citi International Government Inflation-Prote

  • Note: The algorithm computes the probability of correlation between Pfizer Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Pfizer Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Pfizer Inc
    Country United States
    City New York
    Address 66 Hudson Boulevard East
    Phone 212 733 2323
    Website www.pfizer.com
    FullTime employees 83000
    Industry Drug Manufacturers—General
    Sector Healthcare
    Exchange XNYS
    Ticker PFE
    Market www.nyse.com

    Pfizer Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 2.8
    Peer Environment Performance 2.0330864197531
    Environment Percentile unknown
    Palm Oil no
    Nuclear no
    Fur Leather no
    GMO no
    Coal no
    Pesticides no
    Animal Testing yes

    Social scores

    Social ESG Factors Scores
    Social Score 12.9
    Peer Social Performance 14.299012345679
    Social Percentile unknown
    Highest Controversy 3
    Peer Highest Controversy Performance 1.8780487804878
    Adult no
    Gambling no
    Alcoholic no
    Tobacco no
    Catholic yes
    Controversial Weapons no
    Small Arms no
    Military Contract no
    Peer Count yes

    Related Controversy: Society & Community IncidentsBusiness Ethics Incidents


    Governance scores

    Governance ESG Factors Scores
    Governance Score 9.7
    Peer Governance Performance 8.8141975308642
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: 25.3
    Environment Score: 2.8
    Social Score: 12.9
    Governance Score: 9.7

    ESG Performance: AVG_PERF

    Peer Group: Pharmaceuticals

    Peer Esg Score Performance: 25.306097560976

    Rating Year: 2022

    Rating Month: 8

    Max Age: 86400

    Percentile: 45